论文部分内容阅读
目的观察硼替佐米联合地塞米松、环磷酰胺(BCD)在治疗多发性骨髓瘤(MM)患者有效率和安全性以及完全缓解(CR)后的持续时间。方法回顾性分析2008年3月至2012年12月34例MM应用BCD方案治疗后的临床资料,总结应用BCD治疗后的缓解率,缓解持续时间及不良反应。结果采用IMWG制定的疗效标准对所有患者进行疗效评价,32例有效,总有效率ORR 94.11%。获得CR 12例(35.2%)、VGPR 15例(44.1%)、PR 5例(14.7%)、SD 1例(2.9%)、PD 1例(2.9%)。结论硼替佐米联合环磷酰胺和地塞米松对初发和复发难治性多发性骨髓瘤有明显的临床疗效,且药物不良反应较轻,耐受性良好。
Objective To observe the efficacy and safety of bortezomib plus dexamethasone and cyclophosphamide (BCD) in the treatment of patients with multiple myeloma (MM) and the duration of complete remission (CR). Methods The clinical data of 34 patients with MM treated with BCD regimen from March 2008 to December 2012 were retrospectively analyzed. The response rate, duration of remission and adverse reactions after BCD treatment were summarized. Results All the patients were evaluated on the efficacy criteria established by IMWG. All of them were effective in 32 cases, with a total effective rate of 94.11% ORR. CR was found in 12 cases (35.2%), VGPR in 15 cases (44.1%), PR in 5 cases (14.7%), SD in 1 case (2.9%) and PD in 1 case (2.9%). Conclusion Bortezomib combined with cyclophosphamide and dexamethasone have obvious clinical effect on refractory multiple myeloma and relapse-refractory multiple myeloma. The adverse drug reactions are mild and well tolerated.